This site is intended for healthcare professionals
Drug news

Phase III JAVELIN Ovarian 200 trial of avelumab did not meet endpoint in patients with refractory ovarian cancer. Merck KGaA + Pfizer its

Read time: 1 mins
Last updated:20th Nov 2018
Published:20th Nov 2018
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest